Business Description
Adaptimmune Therapeutics PLC
NAICS : 325412
SIC : 2834
ISIN : US00653A1079
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 5.82 | |||||
Equity-to-Asset | 0.14 | |||||
Debt-to-Equity | 0.64 | |||||
Debt-to-EBITDA | -0.2 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -4.88 | |||||
Beneish M-Score | -1.34 | |||||
WACC vs ROIC |
Growth Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 120.5 | |||||
3-Year EBITDA Growth Rate | 10.3 | |||||
3-Year EPS without NRI Growth Rate | 11.6 | |||||
3-Year FCF Growth Rate | -22.2 | |||||
3-Year Book Growth Rate | -57.1 | |||||
Future 3-5Y Total Revenue Growth Rate | -4.38 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 34.64 | |||||
9-Day RSI | 40.28 | |||||
14-Day RSI | 41.96 | |||||
6-1 Month Momentum % | 170.74 | |||||
12-1 Month Momentum % | -1.59 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.85 | |||||
Quick Ratio | 2.85 | |||||
Cash Ratio | 2.02 | |||||
Days Sales Outstanding | 16.63 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13.6 | |||||
Shareholder Yield % | -0.59 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -228.99 | |||||
Net Margin % | -188.9 | |||||
FCF Margin % | -240.86 | |||||
ROE % | -135.55 | |||||
ROA % | -36.99 | |||||
ROIC % | -128.07 | |||||
ROC (Joel Greenblatt) % | -188.09 | |||||
ROCE % | -58.14 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 3.29 | |||||
PB Ratio | 6.55 | |||||
Price-to-Tangible-Book | 7.36 | |||||
EV-to-EBIT | -1.41 | |||||
EV-to-EBITDA | -1.51 | |||||
EV-to-Revenue | 3.22 | |||||
EV-to-Forward-Revenue | 5.93 | |||||
EV-to-FCF | -1.16 | |||||
Earnings Yield (Greenblatt) % | -70.88 | |||||
FCF Yield % | -46.39 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Adaptimmune Therapeutics PLC Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 56.264 | ||
EPS (TTM) (€) | -0.439 | ||
Beta | 2.57 | ||
Volatility % | 114.62 | ||
14-Day RSI | 41.96 | ||
14-Day ATR (€) | 0.065822 | ||
20-Day SMA (€) | 1.02 | ||
12-1 Month Momentum % | -1.59 | ||
52-Week Range (€) | 0.35 - 1.58 | ||
Shares Outstanding (Mil) | 255.56 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Adaptimmune Therapeutics PLC Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Adaptimmune Therapeutics PLC Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Adaptimmune Therapeutics PLC Frequently Asked Questions
What is Adaptimmune Therapeutics PLC(FRA:473A)'s stock price today?
When is next earnings date of Adaptimmune Therapeutics PLC(FRA:473A)?
Does Adaptimmune Therapeutics PLC(FRA:473A) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |